nicotinic receptor alpha4beta2

a nicotinic receptor subtype containing alpha4 and beta2 subunits

Also Known As:

alpha(4)beta(2) nicotinic receptor; alpha4beta2 nicotinic acetylcholine receptor; alpha4beta2 nicotinic receptor; nAChRalpha4beta2; nicotinic receptors alpha4beta2; receptor, nicotinic alpha4beta2

Networked: 23 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Carrier Proteins: 12999
    - Membrane Transport Proteins: 589
      - Ion Channels: 6731
        Ligand-Gated Ion Channels: 221
        Cysteine Loop Ligand-Gated Ion Channel Receptors: 14
        Nicotinic Receptors: 3452
        nicotinic receptor alpha4beta2: 23
  - Membrane Proteins: 10078

Experts

1.	Bertrand, D: 2 articles (05/2010 - 03/2001)
2.	Rigotti, Nancy A: 2 articles (01/2010 - 07/2006)
3.	Tonstad, Serena: 2 articles (01/2010 - 11/2006)
4.	Perry, E K: 2 articles (04/2007 - 04/2004)
5.	Kiguchi, N: 1 article (02/2015)
6.	Kishioka, S: 1 article (02/2015)
7.	Kobayashi, Y: 1 article (02/2015)
8.	Saika, F: 1 article (02/2015)
9.	Asano, Asuka: 1 article (11/2010)
10.	Hasegawa, Mizue: 1 article (11/2010)

Related Diseases

1.	Tobacco Use Disorder (Nicotine Dependence) 03/15/2001 - "Widely expressed in the brain, the alpha4beta2 nicotinic acetylcholine receptor (nAChR) is proposed to play a major role in the mechanisms that lead to and maintain nicotine addiction. " 11/01/2009 - "Varenicline, a novel alpha4beta2 nicotinic receptor partial agonist, is effective for tobacco dependence. " 11/01/2010 - "Varenicline (Champix) is an alpha4beta2 nicotinic receptor antagonist that is used orally for treatment of nicotine dependence. " 04/01/2010 - "Varenicline, alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist, is a new class of medications for treating nicotine dependence. " 05/01/2010 - "Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence."
2.	Stroke (Strokes) 07/01/2002 - "Alpha4beta2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder."
3.	Cardiovascular Diseases (Cardiovascular Disease) 01/19/2010 - "Varenicline, a partial alpha4beta2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown. "
4.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 07/01/2002 - "Alpha4beta2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder."
5.	Parkinson Disease (Parkinson's Disease) 08/01/2009 - "Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease." 02/14/2006 - "This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective alpha4beta2 nicotinic acetylcholine receptor agonist, in 77 individuals with early Parkinson disease. "

Related Drugs and Biologics

1.	Varenicline (Chantix)
2.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
3.	Ethanol (Ethyl Alcohol)
4.	altinicline maleate
5.	Nicotine
6.	Nitric Oxide (Nitrogen Monoxide)
7.	Bungarotoxins (alpha-Bungarotoxin)
8.	Olanzapine (Zyprexa)
9.	dianicline
10.	5-iodo-3-(2-azetidinylmethoxy)pyridine